APIRx... sell retail? I don't think you have a clue.
APIRx is biotech: their main assets are drug candidates and process IP: that didn't change when Incannex acquired them. At the current hour, Incannex remains a pure play biotech. They didn't buy APIRx for the couple of gum products the company had brought to market, but for the 22 clinical and pre-clinical programs the company possesses. You would know this from even a cursory read of any of several company releases on the APIRx acquisition.
IHL Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held